Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide

Andrew A. Bremer, Sayali Ranadive, Robert H. Lustig

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Neonatal diabetes mellitus is rare, may either be transient or permanent, and may be caused by mutations in any of the several different genes. Until recently, most forms of permanent neonatal diabetes required lifelong subcutaneous insulin for management; however, permanent neonatal diabetes due to activating mutations in the KCNJ11 gene, which encodes the Kir6.2 protein subunit of the ATP-sensitive K+ (K ATP) channel, may be amenable to oral sulfonylurea therapy. We describe a case of an 18-month-old infant with permanent neonatal diabetes due to an activating KCNJ11 mutation successfully transitioned from subcutaneous insulin therapy to oral sulfonylurea therapy in the outpatient setting.

Original languageEnglish (US)
Pages (from-to)236-239
Number of pages4
JournalPediatric Diabetes
Volume9
Issue number3 PART 1
DOIs
StatePublished - Jun 2008

Keywords

  • Gyburide
  • KATP channel
  • Kir6.2
  • Neonatal diabetes
  • Sulfonylurea

ASJC Scopus subject areas

  • Internal Medicine
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide'. Together they form a unique fingerprint.

Cite this